Pointon R C, Askill C S, Hunter R D, Wilkinson P M
Cancer Treat Rep. 1981;65 Suppl 1:145-8.
Thirty-four patients with advanced head and neck cancer were treated by synchronous radiotherapy and methotrexate (MTX) (100 mg/m2). Complete resolution of disease was obtained in 18 patients, the median remission of patients being 17 months. In general, treatment was well tolerated, although mucosal reaction was prolonged in 50% of patients. Drug-induced hematological toxicity was observed in six patients (18%) and one patient died. As a result of these findings, a random clinical trial to compare X-ray therapy with X-ray therapy and MTX in advanced head and neck cancer has been commenced.
34例晚期头颈癌患者接受了同步放疗和甲氨蝶呤（MTX，100 mg/m²）治疗。18例患者疾病完全缓解，患者的中位缓解期为17个月。总体而言，治疗耐受性良好，尽管50%的患者黏膜反应有所延长。6例患者（18%）出现了药物引起的血液学毒性，1例患者死亡。基于这些发现，一项比较晚期头颈癌单纯X线放疗与X线放疗联合MTX治疗的随机临床试验已经启动。
